Hospital
Nyu Langone Hospitals
Nyu Langone Hospitals was paid $69.77M by Medicaid between Aug 2019 and Dec 2024, across 465 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 11% of everything it billed.
33Billing provider infoNYU LANGONE HOSPITALS
MINEOLA, NY 11501
MINEOLA, NY 11501
33aNPI1427616002assigned 05/30/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$69.77M
24GClaims1,265,557
24DCodes billed465
24AFirst – last monthAug 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#20 of 231
Median peer was paid$561K
This provider vs. median124×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 71,767 | $3.66M | |
| 2020 | 179,822 | $9.16M | |
| 2021 | 230,968 | $12.04M | |
| 2022 | 265,922 | $14.70M | |
| 2023 | 289,830 | $17.39M | |
| 2024incomplete | 227,248 | $12.81M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 56,892 | 46,933 | $7.77M |
| G0378 | Hospital observation service, per hour | 8.4% | 4,908 | 4,321 | $5.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.5% | 21,574 | 20,879 | $3.86M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.7% | 19,748 | 19,128 | $3.29M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.1% | 18,778 | 17,907 | $2.84M |
| J9271 | Injection, pembrolizumab, 1 mg | 3.8% | 303 | 212 | $2.64M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.4% | 11,765 | 10,805 | $2.37M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 12,108 | 11,700 | $2.17M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.6% | 2,691 | 2,684 | $1.80M |
| C1889 | Implantable/insertable device, not otherwise classified | 2.4% | 5,682 | 5,550 | $1.71M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.3% | 13,162 | 10,065 | $1.58M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2.1% | 578 | 325 | $1.44M |
453 more codes
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.0% | 11,215 | $1.39M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.9% | 10,163 | $1.33M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.7% | 6,642 | $1.18M |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 1.6% | 174 | $1.14M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 6,095 | $1.01M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.4% | 7,315 | $990K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 4,766 | $963K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 4,556 | $945K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.2% | 1,049 | $833K |
| 92552 | 1.1% | 10,493 | $794K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 6,221 | $793K |
| 96415 | 1.1% | 2,463 | $791K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 10,838 | $785K |
| 93975 | 1.1% | 1,543 | $737K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.0% | 1,058 | $719K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.0% | 1,961 | $711K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 3,715 | $504K |
| 93970 | <1% | 1,079 | $453K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,533 | $435K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,279 | $407K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 8,349 | $375K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 33,347 | $371K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,049 | $309K |
| 80076 | <1% | 19,008 | $308K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,387 | $282K |
| 86850 | <1% | 11,415 | $279K | |
| J3490 | Unclassified drugs | <1% | 20,257 | $277K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,139 | $266K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 4,068 | $261K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 16,741 | $261K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,519 | $249K |
| 99173 | <1% | 9,327 | $247K | |
| 86900 | <1% | 11,663 | $246K | |
| J2323 | Injection, natalizumab, 1 mg | <1% | 38 | $246K |
| 99177 | <1% | 7,797 | $241K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 18,814 | $226K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 248 | $224K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,615 | $223K |
| 93976 | <1% | 648 | $222K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,569 | $219K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,525 | $219K |
| 59025 | Fetal non-stress test | <1% | 3,415 | $215K |
| 80053 | Comprehensive metabolic panel | <1% | 16,023 | $214K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,307 | $209K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 590 | $208K |
| 86901 | <1% | 11,676 | $206K | |
| 76641 | <1% | 1,910 | $194K | |
| 36430 | <1% | 807 | $189K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,356 | $167K |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 363 | $166K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,603 | $164K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,399 | $162K |
| D1110 | Prophylaxis - adult | <1% | 3,528 | $162K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,243 | $156K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 22,208 | $156K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,507 | $146K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 767 | $139K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,385 | $136K |
| 95800 | <1% | 472 | $135K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,567 | $133K |
| 76770 | <1% | 481 | $130K | |
| 88342 | <1% | 2,501 | $130K | |
| 54161 | <1% | 120 | $125K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 6,034 | $125K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 160 | $123K |
| C1769 | Guide wire | <1% | 1,173 | $120K |
| 76830 | Ultrasound, transvaginal | <1% | 1,935 | $113K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,061 | $110K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 60,066 | $109K |
| 95806 | <1% | 253 | $103K | |
| D0120 | Dental checkup, returning patient | <1% | 4,121 | $103K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,310 | $98K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 707 | $96K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 410 | $96K |
| 36416 | <1% | 3,747 | $95K | |
| D1120 | Dental cleaning, child | <1% | 2,464 | $95K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 22,239 | $93K |
| 96417 | <1% | 1,592 | $91K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,154 | $90K |
| 95811 | <1% | 131 | $90K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 167 | $88K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 553 | $87K |
| 88307 | <1% | 1,020 | $86K | |
| 80061 | Lipid panel | <1% | 5,001 | $82K |
| 90651 | <1% | 1,713 | $82K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 425 | $81K |
| J0485 | Injection, belatacept, 1 mg | <1% | 84 | $80K |
| 76000 | <1% | 1,129 | $79K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 748 | $78K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 68 | $77K |
| 82803 | <1% | 5,326 | $77K | |
| 77336 | <1% | 346 | $73K | |
| D1206 | Topical application of fluoride varnish | <1% | 2,691 | $70K |
| 90715 | <1% | 2,868 | $67K | |
| 76818 | <1% | 769 | $67K | |
| T2101 | Human breast milk processing, storage and distribution only | <1% | 240 | $66K |
| 88142 | <1% | 2,395 | $63K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 924 | $62K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,894 | $59K |
| 81513 | <1% | 1,893 | $58K | |
| 58558 | <1% | 43 | $57K | |
| 96367 | <1% | 841 | $56K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,966 | $55K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,845 | $55K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 643 | $53K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 308 | $53K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,013 | $51K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,547 | $51K |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 136 | $50K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,066 | $50K |
| 93458 | <1% | 28 | $49K | |
| D0274 | Bitewings - four radiographic images | <1% | 1,821 | $46K |
| 81025 | <1% | 17,576 | $46K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,058 | $46K |
| 87481 | <1% | 1,876 | $46K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 310 | $44K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,587 | $41K |
| 83655 | <1% | 2,860 | $41K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 1,371 | $41K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,193 | $37K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,949 | $36K |
| 90686 | <1% | 9,603 | $36K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 414 | $36K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 2,104 | $36K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,348 | $35K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 193 | $34K |
| 83880 | <1% | 1,780 | $33K | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,188 | $33K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 3,132 | $33K |
| J2704 | Injection, propofol, 10 mg | <1% | 16,406 | $33K |
| D0210 | Intraoral - complete series of radiographic images | <1% | 760 | $33K |
| 77072 | <1% | 399 | $33K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,453 | $33K |
| 77412 | <1% | 109 | $33K | |
| 86481 | <1% | 690 | $32K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,937 | $30K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 622 | $30K |
| 88341 | <1% | 961 | $30K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,183 | $29K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 83 | $28K |
| 88304 | <1% | 1,088 | $27K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 834 | $27K |
| 12001 | <1% | 58 | $26K | |
| 82728 | <1% | 3,866 | $24K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,378 | $23K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 202 | $23K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,026 | $23K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 590 | $20K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,986 | $20K |
| 77065 | Tomosynthesis, mammo | <1% | 244 | $20K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 534 | $20K |
| 84703 | <1% | 5,192 | $20K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 631 | $20K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 93 | $19K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,630 | $19K |
| 51701 | <1% | 44 | $18K | |
| 86780 | <1% | 5,852 | $18K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 264 | $17K |
| 96402 | <1% | 402 | $16K | |
| 81003 | <1% | 15,092 | $16K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,872 | $16K |
| 80069 | <1% | 1,963 | $16K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,135 | $16K |
| 90670 | <1% | 4,752 | $16K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,200 | $15K |
| 77066 | Tomosynthesis, mammo | <1% | 116 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,856 | $15K |
| 76801 | <1% | 152 | $15K | |
| 84702 | <1% | 5,330 | $15K | |
| Q3014 | Telehealth originating site facility fee | <1% | 649 | $14K |
| 70486 | <1% | 314 | $14K | |
| 85610 | <1% | 9,652 | $14K | |
| 96158 | <1% | 98 | $14K | |
| 90647 | <1% | 5,857 | $12K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 708 | $12K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,715 | $12K |
| 96156 | <1% | 133 | $12K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 146 | $12K |
| 77300 | <1% | 60 | $12K | |
| 75574 | <1% | 89 | $12K | |
| 76536 | <1% | 125 | $11K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 408 | $11K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,769 | $11K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $11K |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 1,444 | $11K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,784 | $10K |
| 36591 | <1% | 149 | $10K | |
| 83021 | <1% | 983 | $10K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 1,959 | $10K |
| 77290 | <1% | 25 | $10K | |
| 83735 | <1% | 7,758 | $10K | |
| 86703 | <1% | 663 | $10K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,820 | $10K |
| 90723 | <1% | 4,430 | $9K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 13 | $9K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,122 | $9K |
| 85027 | <1% | 5,095 | $9K | |
| 86803 | <1% | 2,541 | $9K | |
| 90680 | <1% | 4,212 | $9K | |
| 77334 | <1% | 38 | $9K | |
| 90620 | <1% | 177 | $9K | |
| 87070 | <1% | 5,213 | $9K | |
| 83550 | <1% | 2,733 | $8K | |
| 88112 | <1% | 211 | $8K | |
| 90716 | <1% | 1,496 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,136 | $8K |
| 83540 | <1% | 3,011 | $8K | |
| 0071A | <1% | 223 | $8K | |
| 90461 | <1% | 7,015 | $8K | |
| 0072A | <1% | 192 | $8K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 1,082 | $8K |
| 85730 | <1% | 8,503 | $8K | |
| 86769 | <1% | 343 | $8K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,568 | $8K |
| 86923 | <1% | 251 | $8K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 28 | $7K |
| 83615 | <1% | 3,407 | $7K | |
| 84439 | <1% | 2,417 | $7K | |
| 85045 | <1% | 4,125 | $7K | |
| 90633 | <1% | 2,860 | $7K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 57 | $7K |
| 87340 | <1% | 3,375 | $6K | |
| 12011 | <1% | 13 | $6K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 108 | $6K |
| 93798 | <1% | 96 | $6K | |
| 86003 | <1% | 339 | $6K | |
| 70547 | <1% | 28 | $6K | |
| 82784 | <1% | 597 | $6K | |
| 87522 | Neg quan hep c or qual rna | <1% | 161 | $6K |
| 84484 | <1% | 7,938 | $6K | |
| 82948 | <1% | 13,131 | $6K | |
| 82947 | <1% | 1,601 | $6K | |
| 86140 | <1% | 5,191 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,602 | $6K |
| 97802 | <1% | 198 | $5K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,835 | $5K |
| 97161 | <1% | 137 | $5K | |
| D0272 | Bitewings - two radiographic images | <1% | 387 | $5K |
| 76813 | <1% | 138 | $5K | |
| 82248 | <1% | 2,764 | $5K | |
| 84100 | <1% | 3,107 | $5K | |
| 87480 | <1% | 1,100 | $5K | |
| 87660 | <1% | 1,100 | $5K | |
| 87510 | <1% | 1,100 | $5K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 1,007 | $5K |
| 76642 | <1% | 62 | $5K | |
| 90707 | <1% | 1,489 | $5K | |
| 87040 | <1% | 8,386 | $5K | |
| 76820 | <1% | 228 | $5K | |
| 86480 | <1% | 74 | $5K | |
| D0270 | <1% | 324 | $4K | |
| 73630 | <1% | 1,310 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,738 | $4K |
| 87507 | <1% | 63 | $4K | |
| 81001 | <1% | 13,991 | $4K | |
| 83690 | <1% | 9,316 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,468 | $4K |
| 88720 | <1% | 2,497 | $4K | |
| 84550 | <1% | 2,281 | $4K | |
| 0064A | <1% | 107 | $4K | |
| 70496 | <1% | 24 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 116 | $4K |
| 86762 | <1% | 718 | $4K | |
| 96376 | <1% | 1,068 | $4K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 12 | $4K |
| 90710 | <1% | 1,271 | $4K | |
| 73610 | <1% | 1,266 | $4K | |
| 0011A | <1% | 129 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,069 | $4K |
| 82378 | <1% | 447 | $4K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 65 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,951 | $3K |
| 73562 | <1% | 925 | $3K | |
| 90734 | <1% | 581 | $3K | |
| 87631 | <1% | 55 | $3K | |
| 74018 | <1% | 1,916 | $3K | |
| 84153 | <1% | 234 | $3K | |
| 93971 | <1% | 27 | $3K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 26 | $3K |
| 73590 | <1% | 1,096 | $3K | |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | <1% | 107 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,202 | $3K |
| 88185 | <1% | 25 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,050 | $3K |
| 0124A | <1% | 78 | $3K | |
| 76870 | <1% | 94 | $3K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 13 | $3K |
| S0028 | Injection, famotidine, 20 mg | <1% | 3,521 | $3K |
| 87186 | <1% | 2,073 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,619 | $3K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,131 | $3K |
| 85384 | <1% | 1,171 | $3K | |
| 90700 | <1% | 1,381 | $3K | |
| 59430 | <1% | 18 | $3K | |
| 85652 | <1% | 3,916 | $3K | |
| 72100 | <1% | 559 | $3K | |
| 73130 | <1% | 980 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 463 | $2K |
| 90696 | <1% | 1,249 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 635 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 197 | $2K |
| 86787 | <1% | 687 | $2K | |
| 73030 | <1% | 894 | $2K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 119 | $2K |
| 82105 | <1% | 599 | $2K | |
| 83525 | <1% | 420 | $2K | |
| 70544 | <1% | 29 | $2K | |
| 73110 | <1% | 763 | $2K | |
| 74019 | <1% | 503 | $2K | |
| 82607 | <1% | 326 | $2K | |
| 0012A | <1% | 81 | $2K | |
| 82247 | <1% | 1,553 | $2K | |
| 86706 | <1% | 537 | $2K | |
| 82150 | <1% | 970 | $2K | |
| 0054A | <1% | 42 | $2K | |
| 71250 | <1% | 14 | $2K | |
| 86880 | <1% | 97 | $2K | |
| 90656 | <1% | 737 | $2K | |
| 82465 | <1% | 1,190 | $1K | |
| 87486 | <1% | 98 | $1K | |
| 87581 | <1% | 98 | $1K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 754 | $1K |
| 73080 | <1% | 744 | $1K | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 214 | $1K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 33 | $1K |
| 95700 | <1% | 14 | $1K | |
| 90688 | <1% | 619 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,821 | $1K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 519 | $1K |
| 73090 | <1% | 743 | $1K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 241 | $1K |
| 90685 | <1% | 666 | $1K | |
| H1010 | Non-medical family planning education, per session | <1% | 187 | $1K |
| 88184 | <1% | 24 | $1K | |
| D1351 | Sealant - per tooth | <1% | 36 | $1K |
| 84156 | <1% | 768 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 812 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 44 | $1K |
| 80305 | <1% | 1,599 | $989.01 | |
| 86704 | <1% | 272 | $969.05 | |
| 82565 | <1% | 307 | $967.21 | |
| C1758 | Catheter, ureteral | <1% | 169 | $936.50 |
| 85379 | <1% | 1,911 | $918.41 | |
| 82310 | <1% | 249 | $882.29 | |
| 84460 | <1% | 366 | $856.86 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 279 | $853.17 |
| 88261 | <1% | 25 | $846.22 | |
| 72170 | <1% | 186 | $846.03 | |
| 82785 | <1% | 335 | $826.61 | |
| 84075 | <1% | 348 | $806.45 | |
| 84450 | <1% | 388 | $805.05 | |
| 84132 | <1% | 368 | $794.03 | |
| 83718 | <1% | 162 | $788.94 | |
| D2393 | Resin-based composite - three surfaces, posterior, primary or permanent | <1% | 12 | $781.00 |
| 82040 | <1% | 256 | $770.00 | |
| 86701 | <1% | 78 | $749.32 | |
| 82374 | <1% | 241 | $708.07 | |
| 0004A | <1% | 19 | $702.62 | |
| 82746 | <1% | 118 | $702.27 | |
| 84295 | <1% | 247 | $701.70 | |
| 87430 | <1% | 65 | $684.10 | |
| 82435 | <1% | 241 | $681.54 | |
| 82550 | <1% | 650 | $681.12 | |
| 84520 | <1% | 266 | $680.20 | |
| 84155 | <1% | 360 | $646.31 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 2,169 | $642.23 |
| 84478 | <1% | 167 | $622.59 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 203 | $613.27 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 1,476 | $609.10 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 76 | $537.55 |
| 96523 | <1% | 36 | $496.57 | |
| 87081 | <1% | 337 | $484.81 | |
| 83020 | <1% | 79 | $459.28 | |
| 73502 | <1% | 79 | $449.44 | |
| 0134A | <1% | 13 | $396.20 | |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 14 | $395.32 |
| 0002A | <1% | 18 | $390.41 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 68 | $389.46 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 88 | $385.18 |
| 88312 | <1% | 84 | $375.66 | |
| 70498 | <1% | 12 | $372.81 | |
| 90474 | <1% | 496 | $371.32 | |
| 72132 | <1% | 13 | $350.51 | |
| 88360 | <1% | 12 | $343.09 | |
| 86790 | <1% | 64 | $338.90 | |
| 87625 | <1% | 14 | $330.89 | |
| 73552 | <1% | 176 | $314.07 | |
| 87653 | <1% | 13 | $305.11 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12 | $292.38 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 30 | $291.15 |
| 88300 | <1% | 65 | $289.86 | |
| 90697 | <1% | 17 | $277.10 | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 38 | $264.13 |
| 73560 | <1% | 199 | $254.65 | |
| 73060 | <1% | 319 | $254.00 | |
| 87075 | <1% | 99 | $237.17 | |
| 84436 | <1% | 301 | $231.87 | |
| 87205 | <1% | 260 | $222.19 | |
| 82570 | <1% | 63 | $200.73 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 24 | $185.10 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 75 | $184.97 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 118 | $181.92 |
| 0001A | <1% | 15 | $177.85 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 66 | $175.72 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 217 | $167.11 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 27 | $138.87 |
| 81002 | <1% | 411 | $131.55 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 32 | $127.22 |
| 73564 | <1% | 14 | $123.87 | |
| 83516 | <1% | 66 | $120.87 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 550 | $97.83 |
| 87899 | <1% | 12 | $95.58 | |
| 83001 | <1% | 12 | $94.22 | |
| 96368 | <1% | 17 | $89.48 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 472 | $88.12 |
| 88280 | <1% | 25 | $80.24 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 16 | $77.52 |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | <1% | 63 | $77.04 |
| 84145 | <1% | 25 | $70.28 | |
| 82533 | <1% | 15 | $69.50 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 23 | $66.35 |
| 82043 | <1% | 12 | $61.89 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 3,018 | $60.16 |
| 87275 | <1% | 28 | $59.67 | |
| 87045 | <1% | 12 | $58.84 | |
| 88285 | <1% | 25 | $58.44 | |
| 83605 | <1% | 40 | $57.20 | |
| 86665 | <1% | 13 | $52.61 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 18 | $47.44 |
| 86664 | <1% | 13 | $44.34 | |
| 90632 | <1% | 36 | $42.85 | |
| 82010 | <1% | 76 | $41.02 | |
| 94664 | <1% | 27 | $39.03 | |
| 86663 | <1% | 13 | $38.05 | |
| 82977 | <1% | 25 | $26.64 | |
| 89051 | <1% | 27 | $22.64 | |
| 82950 | <1% | 13 | $20.97 | |
| 84480 | <1% | 14 | $18.46 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 90 | $18.08 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 45 | $16.76 |
| 91301 | <1% | 230 | $16.73 | |
| 91312 | <1% | 56 | $15.16 | |
| 91305 | <1% | 46 | $13.56 | |
| 83993 | <1% | 45 | $11.39 | |
| 91300 | <1% | 56 | $8.94 | |
| 85378 | <1% | 13 | $8.75 | |
| 86308 | <1% | 24 | $4.73 | |
| 80320 | <1% | 163 | $4.55 | |
| 91307 | <1% | 16 | $2.80 | |
| 99152 | 0% | 25 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 17 | $0.00 |
| 82962 | 0% | 12 | $0.00 | |
| A4338 | Indwelling catheter; foley type, two-way latex with coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, WESLEY (VP REVENUE CYCLE)
Parent organizationNYU LANGONE HOSPITALS
| Provider | Location | Paid |
|---|---|---|
| Nyu Langone Hospitals | Brooklyn, NY | $303.18M |
| Nyu Langone Hospitals | New York, NY | $238.69M |
| Nyu Langone Hospitals | New York, NY | $117.59M |
| Nyu Langone Hospitals | New York, NY | $32.22M |
| Nyu Langone Hospitals | New York, NY | $3.50M |
| Nyu Langone Hospitals | Brooklyn, NY | $453K |
| Nyu Langone Hospitals | Brooklyn, NY | $99K |
| Nyu Langone Hospitals | Brooklyn, NY | $9K |
| Nyu Hospitals Center | New York, NY | $55.44 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.